Navigation Links
Clinical Study With Investigational Cream Aims To Help Women Who Experience Painful Sex
Date:9/4/2012

NEW YORK, Sept. 4, 2012 /PRNewswire/ -- NeoGyn Vulvar Soothing Cream is sponsoring a clinical study held in four medical centers throughout the United States to test the effectiveness of an investigational cream.

(Photo: http://photos.prnewswire.com/prnh/20120717/NY41829 )

The study is being conducted at The Centers for Vulvovaginal Disorders in Washington DC, Pelvic & Sexual Health Institute in Philadelphia, PA, San Diego Sexual Medicine in San Diego, CA and Arizona Vulva Clinic. Additional applicants are needed for each location to participate in the randomized, double- blind, placebo controlled Research Study to evaluate a vulvar soothing cream containing cutaneous lysate for vulvar use.

Provoked vestibulodynia is classified as spontaneous pain in the vulvar region. The condition is typically characterized by pain at the entry point into the vagina during tampon insertion or sexual intercourse. Causes of provoked vestibulodynia can vary, which contributes to making it difficult for doctors to diagnose and treat this condition.

Each three month study will be led by physicians specialized in the field of women's health and vulvar care including, Dr. Andrew Goldstein, MD, Dr. Kristene Whitmore, MD and Dr. Susan Kellogg PhD, Dr. Irwin Goldstein, MD, and Dr. Joseph Brooks, MD. After inclusion, participants will attend one follow-up clinic visit, two telephone interviews and complete several questionnaires over the course of the study. The study cream and other study related tests, procedures and visits will be provided at no cost to each selected participant.

Eligible applicants are women who live in close proximity to the study sites and are 20-55 years old. Participants cannot be pregnant or breast-feeding and should be in a heterosexual relationship where a reliable form of birth control is being used. Pain experienced with the use of tampons or from intercourse are the top pre-requisites along with no medical history of heart disease, HIV, hepatitis B or C, or being post- menopausal.

NeoGyn's sponsorship of this clinical trial demonstrates the company's commitment to search for solutions in helping women with vulvar pain. The company's mission is also to help educate women and physicians on this not uncommon condition. NeoGyn encourages women to remain persistent in their quest for an accurate diagnosis and solution for vulvodynia

For more information about this clinical study or to see if you qualify, visit http://www.neogynstudy.org. For more information on vestibulodynia, visit http://www.neogyn.us, www.vaginalpainhelp.com, or www.nva.org.


'/>"/>
SOURCE NeoGyn
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
5. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease
8. First Patient Treated in U.S. Clinical Study of Cohera Medicals TissuGlu® Surgical Adhesive
9. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Spain , Dec. 2, 2016 In ... natural sources apart from those derived from C. sativa, ... the Universita` di Napoli Federico II , the ... created the first comprehensive, critical, integrated and unified inventory ... The article focuses on the remarkable chemical and ...
(Date:12/2/2016)... , Dec. 2, 2016  Eli Lilly and ... financial guidance for 2017 and provide updated financial guidance ... also conduct a conference call on that day with ... company,s financial guidance. The conference call will ... general public can access a live webcast of the ...
(Date:12/2/2016)... 2, 2016 CVS Health Corporation (NYSE: ... in New York City on Thursday, December 15, 2016, beginning at 8:00 a.m. ... will provide an in-depth review of the company,s strategies ... company will also discuss 2017 earnings guidance during the ... the event will be broadcast simultaneously on the Investor ...
Breaking Medicine Technology:
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, ... ... today, featuring an inspirational interview of two ostomy patients, standing as living proof ... million people suffer from digestive diseases and issues that spike around the holidays. ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, ... entry through labeling, storing, shipping and disposal. The new version is a faster ...
(Date:12/2/2016)... Wexford, PA (PRWEB) , ... December 02, 2016 , ... ... manages stress and overall health, day and night. No other wearable health technology on ... management. We wanted to give poeple more meaningful insights about their health than ...
(Date:12/2/2016)... ... December 02, 2016 , ... On November 24th, 2016, ... from eight different sites throughout Miami-Dade and Broward counties. This is the largest ... hard on Thanksgiving morning by putting together individual meals via assembly lines and ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
Breaking Medicine News(10 mins):